Antihyperalgesic and analgesic properties of the N‐methyl‐d‐aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia

@article{Klein2008AntihyperalgesicAA,
  title={Antihyperalgesic and analgesic properties of the N‐methyl‐d‐aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia},
  author={Thomas Klein and Walter Magerl and Angelika Hanschmann and Michael Althaus and Rolf-Detlef Treede},
  journal={European Journal of Pain},
  year={2008},
  volume={12}
}
NMDA‐receptors are a major target in the prevention and treatment of hyperalgesic pain states in neuropathic pain. However, previous studies revealed equivocal results depending on study design and efficacy parameters. 
Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain
TLDR
The antinociceptive effect of chronic administration of neramexane is determined and its effect with that of memantine and gabapentin is compared in a rat model of diabetic neuropathic pain to suggest that nerameXane at therapeutically relevant doses attenuates diabetic neuropathy. Expand
Neramexane: a moderate-affinity NMDA receptor channel blocker: new prospects and indications
  • G. Rammes
  • Medicine
  • Expert review of clinical pharmacology
  • 2009
TLDR
Moderate-affinity, voltage-dependent, open-channel blockers, such as memantine and neramexane are useful therapeutics as they prevent the pathological activation of NMDA receptors but allow their physiological activity and should prove to be useful therapeuers in a wide range of CNS disorders. Expand
Human surrogate models of central sensitization: A critical review and practical guide
As in other fields of medicine, development of new medications for management of neuropathic pain has been difficult since preclinical rodent models do not necessarily translate to the clinics. AsideExpand
The role of N‐methyl‐d‐aspartate receptor subunit NR2B in spinal cord in cancer pain
TLDR
The results suggest that NR2B in the spinal cord may participate in bone cancer pain in mice, and ifenprodil may be a useful alternative or adjunct therapy for bone cancerPain. Expand
Experimental characterization of the effects of acute stresslike doses of hydrocortisone in human neurogenic hyperalgesia models
Summary A moderate dose of hydrocortisone reduced capsaicin‐induced secondary hyperalgesia, but not pain to pinprick suggesting an antihyperalgesic action of glucocorticoids consistent withExpand
Opioid-induced Hyperalgesia in Humans: Molecular Mechanisms and Clinical Considerations
TLDR
Clinicians should suspect expression of OIH when opioid treatment effect seems to wane in the absence of disease progression, particularly if found in the context of unexplained pain reports or diffuse allodynia unassociated with the pain as previously observed. Expand
A single nitrous oxide (N2O) exposure leads to persistent alleviation of neuropathic pain in rats.
TLDR
Nitrous oxide exposure induced a persistent reduction of hyperalgesia-allodynia in a rat neuropathic pain model, suggesting that 50% N2O exposure could be an efficient and safe strategy for alleviating neuropathicPain in a persistent manner. Expand
A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models.
TLDR
The present literature review aimed to provide insight into the sensitivity of different hyperalgesia and allodynia models of pharmacological treatment and raised questions about the translatability of these models to the treatment of neuropathic pain. Expand
Unravelling the Mystery of Capsaicin: A Tool to Understand and Treat Pain
TLDR
The rationale of this review is to bring together and discuss the different types of studies that exploit capsaicin actions to shed light upon Capsaicin working both as a tool to understand pain but also as a treatment for chronic pain. Expand
Ion channel blockers for the treatment of neuropathic pain.
TLDR
The biological evidence supporting the involvement of voltage-, proton- and ligand-gated ion channels in the neuropathic pain setting is highlighted and ion channel modulators at different research or development stages are reviewed. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 57 REFERENCES
Novel approaches to targeting glutamate receptors for the treatment of chronic pain: Review article
TLDR
Recently, some novel approaches have been explored as new compounds targeting some modulatory sites at the NMDA receptor (glycineB and NR2B-subtype selective antagonists), as well as kainate and metabotropic glutamate receptors, have been discovered and appear to have a reduced side-effect liability compared to clinically tested NMDA antagonists. Expand
Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans.
TLDR
The analgesic effects of ketamine in the burn injury model are in agreement with results from experimental studies, and can be distinguished from those of local anaesthetics and opioids. Expand
NMDA antagonists and neuropathic pain--multiple drug targets and multiple uses.
TLDR
Agents that are selective for receptors that include the NR2B subunit preclinically have a substantially better profile for treating neuropathic pain than do current NMDA antagonists; some emerging clinical evidence supports this view. Expand
Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists.
TLDR
The present review describes the rational for developing amino-alkyl-cyclohexanes, as new uncompetitive NMDA receptor antagonists based on positive experience with memantine, which has been used clinically for many years for the treatment of neurodegenerative dementia. Expand
Effect of systemic N-methyl-D-aspartate receptor antagonist (dextromethorphan) on primary and secondary hyperalgesia in humans.
TLDR
The effects of dextromethorphan in the burn injury model were similar to those of ketamine and distinct from those of local anaesthetics and opioids. Expand
Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects
TLDR
The results of this study suggest that neural systems sensitive to NMDA receptor antagonists and opioids participate in capsaicin‐evoked pain phenomena, and support the feasibility of pharmacological studies using the intradermal Capsaicin model. Expand
Differential Modulation of Remifentanil-induced Analgesia and Postinfusion Hyperalgesia by S-Ketamine and Clonidine in Humans
TLDR
Opioid-induced postinfusion hyperalgesia could be abolished by S-ketamine, suggesting an N-methyl-d-aspartate-receptor mechanism, while elevated pain ratings after infusion were not reduced by ketamine but were alleviated by the &agr;2-recept agonist clonidine. Expand
Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists –in vitro characterisation
TLDR
Initial characterization in animal models provides strong support for the belief that MRZ 2/579 could be a useful therapeutic in morphine/alcohol dependence, inhibition of morphine tolerance, chronic pain and as a neuroprotective agent. Expand
Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels
TLDR
A global model was developed in which flupirtine stabilizes the resting membrane potential by activating inwardly rectifying K+ channels, thus indirectly inhibiting the activation of NMDA receptors. Expand
Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action
TLDR
It is concluded that tricyclic antidepressants in optimal doses appear to be the most efficient treatment of neuropathic pain, but some of the other treatments may be important due to their better tolerability. Expand
...
1
2
3
4
5
...